SEARCH

SEARCH BY CITATION

References

  • 1
    Eastell, R., Arnold, A., Brandi, M.L. et al. (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism, 94, 340350.
  • 2
    Marcocci, C. & Cetani, F. (2011) Clinical practice Primary hyperparathyroidism. The New England Journal of Medicine, 365, 23892397.
  • 3
    Fraser, W.D. (2009) Hyperparathyroidism. Lancet, 374, 145158.
  • 4
    Bollerslev, J., Marcocci, C., Sosa, M. et al. (2011) Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. European Journal of Endocrinology, 165, 851864.
  • 5
    Udelsman, R., Pasieka, J.L., Sturgeon, C. et al. (2009) Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism, 94, 366372.
  • 6
    Khan, A., Grey, A. & Shoback, D. (2009) Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism, 94, 373381.
  • 7
    Diaz-Soto, G., Linglart, A., Senat, M.V. et al. (2013) Primary hyperparathyroidism in pregnancy. Endocrine, doi: 10.1007/s12020-013-9980-4.
  • 8
    Saponaro, F., Faggiano, A., Grimaldi, F. et al. (2013) Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clinical Endocrinology, 79, 2026.
  • 9
    Kouvaraki, M.A., Greer, M., Sharma, S. et al. (2006) Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns of endocrine surgery. Surgery, 139, 527534.
  • 10
    Kunstman, J.W., Kirsch, J.D., Mahajan, A. et al. (2013) Clinical review: parathyroid localization and implications for clinical management. Journal of Clinical Endocrinology and Metabolism, 98, 902912.
  • 11
    Bilezikian, J.P., Khan, A.A. & Potts, J.T. Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Journal of Clinical Endocrinology and Metabolism, 94, 335339.
  • 12
    Stewart, A.F. (2005) Clinical practice. Hypercalcemia associated with cancer. New England Journal of Medicine, 352, 373379.
  • 13
    Khan, A.A. (2013) Medical management of primary hyperparathyroidism. Journal of Clinical Densitometry : The Official Journal of the International Society for Clinical Densitometry, 16, 6063.
  • 14
    Marcocci, C., Chanson, P., Shoback, D. et al. (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 94, 27662772.
  • 15
    Peacock, M., Bilezikian, J.P., Bolognese, M.A. et al. (2011) Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. Journal of Clinical Endocrinology and Metabolism, 96, E9E18.
  • 16
    Peacock, M., Bolognese, M.A., Borofsky, M. et al. (2009) Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. Journal of Clinical Endocrinology and Metabolism, 94, 48604867.
  • 17
    Zanocco, K., Angelos, P. & Sturgeon, C. (2006) Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery, 140, 874881. discussion 881–872.
  • 18
    Yu, N., Donnan, P.T. & Leese, G.P. (2011) A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clinical Endocrinology, 75, 169176.
  • 19
    Eller-Vainicher, C., Cairoli, E., Zhukouskaya, V. et al. (2013) Prevalence of subclinical contributors to low BMD and/or fragility fracture. European Journal of Endocrinology, 169, 225237.
  • 20
    Horwitz, M.J. (2011) What medical options should be considered for the treatment of primary hyperparathyroidism? Clinical Endocrinology, 75, 592595.
  • 21
    Tassone, F., Gianotti, L., Baffoni, C. et al. (2013) Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clinical Endocrinology, 79, 784790.
  • 22
    Wagner, D., Xia, Y. & Hou, R. (2013) Safety of vitamin D replacement in patients with primary hyperparathyroidism and concomitant vitamin D deficiency. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 19, 420425.
  • 23
    Grey, A. (2012) Nonsurgical management of mild primary hyperparathyroidism – a reasonable option. Clinical Endocrinology, 77, 639644.
  • 24
    Witteveen, J.E., van Thiel, S., Romijn, J.A. et al. (2013) Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. European Journal of Endocrinology, 168, R45R53.
  • 25
    Khan, A.A., Bilezikian, J.P., Kung, A.W. et al. (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 89, 33193325.
  • 26
    Chow, C.C., Chan, W.B., Li, J.K. et al. (2003) Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 581587.
  • 27
    Rossini, M., Gatti, D., Isaia, G. et al. (2001) Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. Journal of Bone and Mineral Research, 16, 113119.
  • 28
    Rubin, M.R., Lee, K.H., McMahon, D.J. et al. (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 11741178.
  • 29
    Haglund, F., Ma, R., Huss, M. et al. (2012) Evidence of a functional estrogen receptor in parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism, 97, 46314639.
  • 30
    Amaral, L.M., Queiroz, D.C., Marques, T.F. et al. (2012) Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: more Stone than Bone? Journal of Osteoporosis, 2012, 128352.
  • 31
    Lowe, H., McMahon, D.J., Rubin, M.R. et al. (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. Journal of Clinical Endocrinology and Metabolism, 92, 30013005.
  • 32
    Starup-Linde, J., Waldhauer, E., Rolighed, L. et al. (2012) Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables. European Journal of Endocrinology, 166, 10931100.
  • 33
    Rejnmark, L., Vestergaard, P. & Mosekilde, L. (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 96, 23772385.
  • 34
    Sorensen, M.D., Duh, Q.Y., Grogan, R.H. et al. (2012) Differences in metabolic urinary abnormalities in stone forming and nonstone forming patients with primary hyperparathyroidism. Surgery, 151, 477483.